Influence of specific endothelin-1 receptor blockers on hemodynamic parameters and antioxidant status of plasma in LPS-induced endotoxemia

Pharmacological Reports

Volumn 64, Issue 6, 2012, Pages 1434-1441

  Piechota Polańczyk, Aleksandra ^a   Gora̧ca, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Blood hemodynamics; BQ123; BQ788; Endotoxic shock; Oxidative stress

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ENDOTOXEMIA; HEMODYNAMICS; LIPID PEROXIDATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPECTROPHOTOMETRY; SYSTOLIC BLOOD PRESSURE;

EID: 84873730537     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70941-6     Document Type: Article

References (43)

1. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL: Endothelium-restricted overexpression of human endothelin-1 causes vascular remodelling and endothelial dysfunction. Circulation, 2004, 110, 2233-2240. (Pubitemid 39372507)
2. Ayala A, Chaudry JH: Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock, 1996, 6, 27-38.
3. Blalock SE, Matulevicius S, Mitchell LC, Reimold S, Warner J, Peshock R, Torres F. Chin KM: Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail, 2010, 16, 121-127.
4. Benzie IFF, Strain JJ: The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem, 1996, 239, 70-76.
5. Cai H, Griendling KK, Harrison DG: The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci, 2003, 24, 471-478. (Pubitemid 37088172)
6. El-Awady MS, Smirnov SV, Watson ML: Desensitization of the soluble guanylyl cyclase/cGMP pathway by lipo-polysaccharide in rat isolated pulmonary artery but not aorta. Br J Pharmacol, 2008, 155, 1164-1173.
7. El-Awady MS, Smirnov SV, Watson ML: Voltage-independent calcium channels mediate lipopolysaccha-ride- induced hyporeactivity to endothelin-1 in the rat aorta. Am J Physiol Heart Circ Physiol, 2009, 296, H1408-415.
8. Elferink JG, de Koster BM: Endothelin-induced activation of neutrophil migration. Biochem Pharmacol, 1994, 48, 865-871. (Pubitemid 24285163)
9. Fenhammar J, Andersson A, Frithiof R, Forestier J, Weitzberg E, Sollevi A, Hjelmqvist H: The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock. Acta Anaesthesiol Scand, 2008, 52, 1385-1393.
10. Filep JG: Role of endogenous endothelin in the regulation of plasma volume and albumin escape during endotoxin shock in conscious rats. Br J Pharmacol, 2000, 129, 975-983.
11. Ford RL, Mains IM, Hilton EJ, Reeves ST, Stroud RE, Crawford FAJr, Ikonomidis JS, Spinale FG: Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation. Ann Thorac Surg, 2008, 86, 1576-1583.
12. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun, 1999, 199, 1461-1465.
13. Galley HF, Webster NR: Physiology of the endothelium. Br J Anaesth, 2004, 93, 105-113. (Pubitemid 38967432)
14. Ge Z, Jiang G, Zhao Y, Wang G, Tan Y: Systemic perfluorohexane attenuates lung injury induced by lipopolysaccharide in rats: the role of heme oxygenase-1. Pharmacol Rep, 2010, 62, 170-177.
15. Gryglewski RJ, Wolkov PP, Uracz W, Janowska E, Bartus JB, Balbatun O, Patton S et al.: Protective role of pulmonary nitric oxide in the acute phase of endotoxemia in rats. Circ Res, 1998, 82, 819-827. (Pubitemid 28185850)
16. Halcox JP, Nour KR, Zalos G, Quyyumi A: Endogenous endothelin in human coronary vascular function. Hypertention, 2007, 49, 1134-1141.
17. Hållström L, Berghäll E, Frostell C, Sollevi A, Soop AL: Nitric oxide inhalation and glucocorticoids as combined treatment in human experimental endotoxemia. Crit Care Med, 2008, 36, 3043-3047.
18. Helset E, Sildnes T, Konopski ZS: Endothelin-1 stimulates monocytes in vitro to release chemotactic activity identified as interleukin-8 and monocyte chemotactic protein-1. Mediators Inflamm, 1994, 3, 155-160. (Pubitemid 24131933)
19. Hirata Y, Ishimaru S: Effects of endothelin receptor antagonists on endothelin-1 and inducible nitric oxide synthase genes in a rat endotoxic shock model. Clin Sci (Lond), 2002, 103, 332S-335S. (Pubitemid 35007182)
20. Juergens UR, Racké K, Uen S, Haag S, Lamyel F, Stöber M, Gillissen A et al.: Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: new evidence for beneficial anti-inflammatory potency of ETB-receptor antagonism. Pulm Pharmacol Ther, 2008, 21, 533-539. (Pubitemid 351625935)
21. Kiriş I, Narin C, Gülmen S, Yilmaz N, Sütçü R, Kapucuoǧlu N: Endothelin receptor antagonism by tezosentan attenuates lung injury induced by aortic ischemia-reperfusion. Ann Vasc Surg, 2009, 23, 382-391.
22. Kuklin VN, Kirov MY, Evgenov OV, Sovershaev MA, Sjöberg J, Kirova SS, Bjertnaes LJ: Novel endothelin receptor antagonist attenuates endotoxin-induced lung injury in sheep. Crit Care Med, 2004, 2, 766-773. (Pubitemid 38340075)
23. Litmathe J, Boeken U, Bohlen G, Gursoy D, Sucker C, Feindt P: Systemic inflammatory response syndrome after extracorporeal circulation: a predictive algorithm for the patient at risk. Hellenic J Cardiol, 2011, 52, 493-500.
24. Matsuura T, Yukimura T, Kim S, Miura K, Iwao H: Selective blockade of endothelin receptor subtypes on systemic and renal vascular responses to endothelin-1 and IRL1620, a selective endothelin ETB-receptor agonist, in anesthetized rats. Jpn J Pharmacol, 1996, 71, 213-222. (Pubitemid 26264265)
25. Nitescu N, Grimberg E, Ricksten SE, Herlitz H, Guron G: Endothelin B receptors preserve renal blood flow in a normotensive model of endotoxin-induced acute kidney dysfunction. Shock, 2008, 29, 402-409. (Pubitemid 351271714)
26. Oldner A, Wanecek M, Weitzberg E, Sundin P, Sollevi A, Rubio C, Hellström PM: Differentiated effects on splanchnic homeostasis by selective and non-selective endothelin receptor antagonism in porcine endotoxaemia. Br J Pharmacol, 1999, 127, 1793-804. (Pubitemid 29392873)
27. Piechota A, Polańczyk A, Gora̧ca A: Protective effects of endothelin-A receptor antagonist BQ123 against LPS-induced oxidative stress in lungs. Pharmacol Rep, 2011, 63, 494-500.
28. Pittet JF, Morel DR, Hemsen A, Gunning K, Lacroix JS, Suter PM, Lundberg JM: Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg, 1991, 213, 261-264.
29. q-pathways and MAP kinase activation. Br J Pharmacol, 2008, 154, 13-24.
30. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, Lennon R et al.: Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation, 2010, 122, 958-966.
31. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS: Endothelin Areceptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. Hypertension, 2007, 49, 893-901.
32. Schinelli S, Zanassi P, Paolillo M, Wang H, Avvedimento EV, Gallo V: Stimulation of endothelin B receptors in astrocytes induces cAMP response element binding protein (CREB) phosphorylation and c-fos expression via multiple mitogen-activated protein kinase (MAPK) signalling pathways. J Neurosci, 2001, 21, 8842-8853. (Pubitemid 33054848)
33. Schorlemmer A, Matter ML, Shohet RV: Cardioprotective signalling by endotelin. Trends Cardiovasc Med, 2008, 18, 233-239.
34. Sebai H, Ben-Attia M, Sani M, Aouani E, Ghanem- Boughanmi N: Protective effect of resveratrol in endotoxemia-induced acute phase response in rats. Arch Toxicol, 2009, 83, 335-340.
35. Skibska B, Józefowicz-Okonkwo G, Gora̧ca A: Protective effects of early administration of α-lipoic acid against lipopolysaccharide-induced plasma lipid peroxidation. Pharmacol Rep, 2006, 58, 399-404. (Pubitemid 44111075)
36. Sprague AH, Khalil RA: Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol, 2009, 78, 539-552.
37. Victor VM, De La Fuente M: Changes in the superoxide production and other macrophage functions could be related to the mortality of mice with endotoxin-induced oxidative stress. Physiol Res, 2003, 52, 101-110. (Pubitemid 36356267)
38. Viel EC, Benkirane K, Javeshghani D, Touyz RM, Schiffrin EL: Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol, 2008, 295, H281-288.
39. Wanecek M, Oldner A, Rudehill A, Sollevi A, Alving K, Weitzberg E: Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan. Shock, 1997, 7, 364-370. (Pubitemid 127654294)
40. Wanecek M, Weitzberg E, Rudehill A, Oldner A: The endothelin system in septic and endotoxin shock. Eur J Pharmacol, 2000, 27, 1-15.
41. Wexberg P, Sperker W, Morgenthaler NG, Heinzl H, Adlbrecht C, Plass C, Glogar HD et al.: Inhomogeneous vasomotor effects of moderate selective and nonselective endothelin-receptor blockade in stable coronary artery disease. Heart, 2009, 95, 1258-1264.
42. Xiao H, Sun Z, Zhang H, Zhang D: Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacol Rep, 2012, 64, 889-895.
43. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1988, 332, 411-415. (Pubitemid 18090241)